ライフサイエンスコーパス: PCNSL

1 PCNSL in immunocompetent patients is associated with uni

2 PCNSL incidence was higher in Asians/Pacific Islanders t

3 PCNSL is an uncommon tumor, and only four randomized tri

4 PCNSL is highly dependent on BCR signaling, and ibrutini

5 PCNSL patients without evidence of radiographic disease

6 In 18 PCNSL patients, 94% showed tumor reductions with ibrutin

7 xpression and function were assessed in AIDS-PCNSL biopsy samples and in EBV+ human B-cell tumors tha

8 rimary central nervous system lymphoma (AIDS-PCNSL) is due in part to the intrinsic resistance of thi

9 omponent in the multimodal treatment of AIDS-PCNSL.

10 Cells from two AIDS-PCNSL biopsy samples that did not express pan B-cell mar

11 Because PCNSL may involve the brain, CSF, and eyes, diagnostic e

12 nome-wide gene expression comparison between PCNSL and non-CNS DLBCL was performed, the latter consis

13 ebral endothelial cells upon CNS invasion by PCNSL.

14 Primary lymphoma of the CNS (PCNSL) is a diffuse large B cell lymphoma confined to th

15 In conclusion, PCNSL risk is highly elevated among transplant recipient

16 had undergone repeat brain biopsy to confirm PCNSL.

17 Stereotactic biopsy confirmed PCNSL due to Ebstein-Barr virus reactivation.

18 mpetent adults with histologically confirmed PCNSL after experiencing high-dose methotrexate-based ch

19 utive patients with histologically confirmed PCNSL were collected concurrently with magnetic resonanc

20 in, all 24 brain biopsy specimens containing PCNSL were positive for BCA-1.

21 a true "CNS signature" because we contrasted PCNSL with wide-spectrum non-CNS DLBCL on a genomic scal

22 single-center phase-2 study, newly diagnosed PCNSL patients received 5 to 7 cycles of chemotherapy wi

23 ht consecutive patients with newly diagnosed PCNSL seen at Memorial Sloan-Kettering Cancer Center (MS

24 Forty-four patients with newly diagnosed PCNSL were treated with induction MT-R, and patients who

25 is feasible in patients with newly diagnosed PCNSL without evidence of significant related neurotoxic

26 ll survival in patients with newly diagnosed PCNSL.

27 plicability to patients with newly diagnosed PCNSL.

28 ncreased the probability for differentiating PCNSL and atypical glioblastoma compared with the evalua

29 e diagnostic performance for differentiating PCNSL from glioblastoma was evaluated by using logistic

30 and genetic characteristics that distinguish PCNSL are beginning to be elucidated.

31 g a preclinical animal model of human EBV(+) PCNSL with subsequent translation to patients with EBV(+

32 Enhanced expression of EBV-TK mRNA in EBV(+) PCNSL tumors by radiation therapy occurred in a dose-dep

33 have developed a preclinical model of EBV(+) PCNSL to explore strategies that specifically target EBV

34 Patients with EBV(+) PCNSL face a particularly poor prognosis with median sur

35 a solid organ transplant patient with EBV(+) PCNSL.

36 bsequent translation to patients with EBV(+) PCNSL.

37 wledge that dose-intensive consolidation for PCNSL is feasible in the multicenter setting and yields

38 eral biologic contexts with implications for PCNSL, including CNS tropism (ECM and adhesion-related p

39 splant recipients had elevated incidence for PCNSL compared with the general population (standardized

40 d that this appears to be a prerequisite for PCNSL development, we find no evidence that pleomorphic

41 Combined modality therapy for PCNSL has improved survival, but relapse is common and l

42 h ibrutinib alone, including patients having PCNSL with CD79B and/or MYD88 mutations, and 86% of eval

43 Virus (EBV) positive, in contrast to non-HIV PCNSL and non-CNS AIDS-related lymphomas.

44 tive review was performed of immunocompetent PCNSL patients from 1985 to 2005.

45 In PCNSL, expression of BCA-1 by malignant lymphocytes and

46 ally analyze reported studies on HDC/ASCT in PCNSL and discuss its current role and future perspectiv

47 The rationale for using HDC/ASCT in PCNSL patients is based on the fact that the delivery of

48 alysis of molecular prognostic biomarkers in PCNSL in the setting of a clinical trial.

49 tein level of ECM-related SPP1 and CHI3L1 in PCNSL cells was demonstrated by immunohistochemistry.

50 )(q22) and BCL6 rearrangements are common in PCNSL and predict for decreased OS independent of deep s

51 hough intraocular involvement is frequent in PCNSL and clinically marked by slowly progressive visual

52 ed studies detected high EBV copy numbers in PCNSL tumour tissue, and low copy numbers in AIDS cases

53 ive chemotherapy in this randomized trial in PCNSL, in which neither arm involves WBRT.

54 of high-dose consolidation, without WBRT, in PCNSL.

55 imaging (MRI) according to the International PCNSL Collaborative Group response criteria.

56 IGH), and MYC gene rearrangements in a large PCNSL cohort treated in a single center.

57 , including those with primary CNS lymphoma (PCNSL) (outside the area of neoplastic involvement) cont

58 Primary CNS lymphoma (PCNSL) and primary intraocular lymphoma (IOL) are usuall

59 response assessment of primary CNS lymphoma (PCNSL) are critical to ensure comparability among clinic

60 Primary CNS lymphoma (PCNSL) harbors mutations that reinforce B cell receptor

61 s with newly diagnosed primary CNS lymphoma (PCNSL) in order to establish a predictive model that cou

62 Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma

63 Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validate

64 Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumor.

65 PURPOSE Primary CNS lymphoma (PCNSL) is confined to the CNS and/or the eyes at present

66 ed on 31 patients with primary CNS lymphoma (PCNSL) treated between 1986 and 1992 with methotrexate (

67 atients with recurrent primary CNS lymphoma (PCNSL) were studied.

68 Primary CNS lymphoma (PCNSL), an uncommon form of extranodal non-Hodgkin's lym

69 vival in patients with primary CNS lymphoma (PCNSL).

70 (RT) for patients with primary CNS lymphoma (PCNSL).

71 relapsed or refractory primary CNS lymphoma (PCNSL).

72 es as consolidation in primary CNS lymphoma (PCNSL).

73 -dose methotrexate for primary CNS lymphoma (PCNSL).

74 imary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma (PTL) are rare ex

75 imary central nervous system (CNS) lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confin

76 sease, and primary central nervous lymphoma (PCNSL).

77 Primary central nervous system lymphoma (PCNSL) in HIV patients has declined in incidence and the

78 Primary central nervous system lymphoma (PCNSL) is a rare but often rapidly fatal form of non-Hod

79 Primary central nervous system lymphoma (PCNSL) is an aggressive B cell lymphoma that occurs in i

80 in primary central nervous system lymphoma (PCNSL) is caused mostly by intraocular lymphomatous invo

81 Primary central nervous system lymphoma (PCNSL) represents 1% to 3% intracranial tumors.

82 Primary central nervous system lymphoma (PCNSL) risk is greatly increased in immunosuppressed hum

83 Primary central nervous system lymphoma (PCNSL) that arises in immune-deficient patients is an ag

84 Primary central nervous system lymphoma (PCNSL) treatment includes 2 phases: induction and consol

85 sed primary central nervous system lymphoma (PCNSL) using induction immunochemotherapy (rituximab, hi

86 of primary central nervous system lymphoma (PCNSL), but relapses remain frequent.

87 of primary central nervous system lymphoma (PCNSL).

88 of primary central nervous system lymphoma (PCNSL).

89 orphic infiltrates represent a pre-malignant PCNSL state.

90 Most PCNSL are located in the brain, and 75% are large B-cell

91 o explain, at least in part, the affinity of PCNSL cells for the CNS.

92 rs, we have analyzed V(H) gene of 5 cases of PCNSL, all confirmed by histological studies to be Epste

93 ain lesions strongly suggests a diagnosis of PCNSL.

94 of PWI and DWI facilitated the diagnosis of PCNSL.

95 of ITSS allowed reliable differentiation of PCNSL and atypical glioblastoma in most patients, and th

96 To identify targetable genetic features of PCNSL and PTL, we characterized their recurrent somatic

97 The incidence of PCNSL is rising in immunocompetent patients over the age

98 f therapy and address the quality of life of PCNSL survivors.

99 The majority of PCNSL patients who received corticosteroids before diagn

100 re improving the diagnosis and management of PCNSL.

101 an atypical and challenging presentation of PCNSL.

102 ns remain regarding the optimal treatment of PCNSL, in general, and unusual variants of PCNSL.

103 advances have improved our understanding of PCNSL, the need for additional collaborative research is

104 f PCNSL, in general, and unusual variants of PCNSL.

105 mes that are comparable or superior to other PCNSL treatment regimens.

106 In vivo trials using the nude rat PCNSL model demonstrated significantly improved mean sur

107 Compared to kidney recipients, PCNSL incidence was lower in liver recipients (adjusted

108 ns for patients with relapsed and refractory PCNSL and PTL, and the overall prognosis is poor.

109 umab, in 4 patients with relapsed/refractory PCNSL and 1 patient with CNS relapse of PTL.

110 t nivolumab is active in relapsed/refractory PCNSL and PTL and support further investigation of PD-1

111 Virtually all AIDS-related PCNSL are known to be Epstein-Barr Virus (EBV) positive,

112 s showed EBV positivity only in AIDS-related PCNSL cases within the lymphoma deposits.

113 However, the incidence of AIDS-related PCNSL, which is related to Epstein-Barr virus infections

114 tive Radiation Therapy Oncology Group (RTOG) PCNSL clinical trials was used to test the RPA classific

115 17 cancer registries (1987-2014), we studied PCNSL and systemic non-Hodgkin lymphoma (NHL) in 288 029

116 MRI techniques such as DWI and PWI suggested PCNSL.

117 is with the program SigPathway revealed that PCNSL is characterized notably by significant differenti

118 Thus, PCNSL Ig may recognize CNS proteins as self-Ags.

119 rminal center formation in the brain tissue, PCNSL is derived from a B cell with features associated

120 tion is an effective therapeutic approach to PCNSL, but neurotoxicity is a delayed risk of this appro

121 e III EBV gene expression profile similar to PCNSL that develops in some immune-deficient patients.

122 ncluding all Abs derived from IGHV4-34 using PCNSL, recognized galectin-3, which was upregulated on m

123 A total of 752 patients diagnosed with PCNSL were retrospectively identified from the databases

124 mmunocompetent patients newly diagnosed with PCNSL.

125 TSS was significantly lower in patients with PCNSL (32% [six of 19]) than in those with glioblastoma

126 c results in 95% (18 of 19) of patients with PCNSL and 96% (27 of 28) of patients with atypical gliob

127 The prognosis of patients with PCNSL has improved during the last decades with the intr

128 The outcome for patients with PCNSL is rapidly improving with new treatment strategies

129 Vs were significantly lower in patients with PCNSL than in those with glioblastoma (P < .01, respecti

130 brain biopsy specimens from 24 patients with PCNSL to investigate the expression of B cell-attracting

131 diagnosed (with no prior WBRT) patients with PCNSL treated with osmotic BBBD and intra-arterial (IA)

132 Forty-five patients with PCNSL were accrued.

133 eficiency virus (HIV)-negative patients with PCNSL were entered on study and received two (n = 20) or

134 For patients with PCNSL who experience treatment failure with methotrexate

135 In patients with PCNSL, serum levels of YKL-40 and MMP-9 are associated w

136 d treatment of immunocompetent patients with PCNSL.

137 irradiation in newly diagnosed patients with PCNSL.

138 ove survival over RT alone for patients with PCNSL.

139 lastoma and 19 immunocompetent patients with PCNSL.

140 ot MMP-9, predicts survival in patients with PCNSL.

141 wly diagnosed, immunocompetent patients with PCNSL; 98 were assessable.

142 active in relapsed/refractory patients with PCNSL; however, responses were usually short lived.

143 Recipients with PCNSL also had higher mortality than those with systemic

144 Compared to other recipients, those with PCNSL had increased risk of death (adjusted hazard ratio